Biocytogen’s business development team is pleased to exhibit and host 1-on-1 meetings at BIO KOREA 2023, taking place from May 10-12, 2023 in Seoul, South Korea.
Join us at booth C5 to learn more about our 6 proprietary fully human antibody discovery RenMiceTM platforms: monoclonal antibody (RenMabTM), bispecific antibody and bispecific ADC (RenLite®), nanobody (RenNano®), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and our RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets.
With this streamlined antibody development capability, Biocytogen launched Project Integrum, an initiative to develop therapeutic antibodies for more than 1000+ targets. Since the initiation of Project Integrum, the company has generated 6 clinical stage assets and numerous preclinical stage assets (10+ fully human bispecific antibodies, 20+ bispecific antibody-drug conjugates, 10+ TCR-mimic antibodies, 30+ monoclonal antibodies, and 600+ antibody hits).
Biocytogen’s antibody assets and RenMice platforms have been recognized by many pharmaceutical and biotech companies. As of December 31, 2022, Biocytogen has reached 34 preclinical antibody co-development or licensing agreements with 21 companies, including Merck Healthcare KGaA, ADC Therapeutics, Hansoh Pharma, Chipscreen NewWay, LiberoThera, RemeGen, China Resources Biopharm and Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ). Additionally, the company has licensed RenMice (RenMab/RenLite) to 17 companies, including Merck Healthcare KGaA, Janssen, BeiGene, Xencor and Innovent; 40 projects have initiated.
Biocytogen’s sub-brand BioMice provides preclinical contract research services and products, including gene editing services, animal model development and sales, and preclinical pharmacology evaluation services. Our innovative animal models have been sold to more than 20 countries and regions around the world, and we have offered more than 2,000 preclinical pharmacology and efficacy evaluation services for over 400 clients globally.
Whether you’re interested in our antibody discovery platforms, therapeutic antibody assets, or our BioMice models, we look forward to exploring collaboration opportunities with you at the event! To schedule a meeting with us, please contact our APAC team at info@bbctg.com.cn.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum (RenMiceTM HiTS Platform). As of December 31, 2022, 34 therapeutic antibody co-development/out-licensing/transfer agreements and 17 RenMiceTM licensing agreements have been established worldwide, including several partnerships with multinational pharmaceutical companies. Biocytogen's pipeline is comprised of 11 core assets, with partnerships established for 4 out of 6 total clinical assets. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
Biocytogen’s Contacts
APAC business development team: info@bbctg.com.cn
Media: pr@bbctg.com.cn
